OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
Geoffrey A. Block, David P. Rosenbaum, Andrew T. Yan, et al.
Nephrology Dialysis Transplantation (2018) Vol. 34, Iss. 2, pp. 339-346
Open Access | Times Cited: 36
Geoffrey A. Block, David P. Rosenbaum, Andrew T. Yan, et al.
Nephrology Dialysis Transplantation (2018) Vol. 34, Iss. 2, pp. 339-346
Open Access | Times Cited: 36
Showing 26-50 of 36 citing articles:
Potentielle application de l’axe fibroblast growth factor 23-Klotho dans la maladie rénale chronique
Jean Sébastien Lacroix, Pablo Ureña-Torres
Néphrologie & Thérapeutique (2019) Vol. 16, Iss. 2, pp. 83-92
Closed Access | Times Cited: 6
Jean Sébastien Lacroix, Pablo Ureña-Torres
Néphrologie & Thérapeutique (2019) Vol. 16, Iss. 2, pp. 83-92
Closed Access | Times Cited: 6
Effects of EOS789, a novel pan-phosphate transporter inhibitor, on phosphate metabolism : Comparison with a conventional phosphate binder
Kazuya Tanifuji, Yuji Shiozaki, Megumi Koike, et al.
The Journal of Medical Investigation (2023) Vol. 70, Iss. 1.2, pp. 260-270
Open Access | Times Cited: 2
Kazuya Tanifuji, Yuji Shiozaki, Megumi Koike, et al.
The Journal of Medical Investigation (2023) Vol. 70, Iss. 1.2, pp. 260-270
Open Access | Times Cited: 2
Hyperphosphataemia in 2019
A. Hutchison, Ron Wald, Thomas F. Hiemstra
Current Opinion in Nephrology & Hypertension (2019) Vol. 28, Iss. 5, pp. 441-447
Closed Access | Times Cited: 5
A. Hutchison, Ron Wald, Thomas F. Hiemstra
Current Opinion in Nephrology & Hypertension (2019) Vol. 28, Iss. 5, pp. 441-447
Closed Access | Times Cited: 5
The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?
Lorenza Magagnoli, Mario Cozzolino, Andrea Galassi
Clinical Kidney Journal (2023) Vol. 16, Iss. 10, pp. 1543-1549
Open Access | Times Cited: 1
Lorenza Magagnoli, Mario Cozzolino, Andrea Galassi
Clinical Kidney Journal (2023) Vol. 16, Iss. 10, pp. 1543-1549
Open Access | Times Cited: 1
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Giuseppe Vergaro, Annamaria Del Franco, Alberto Aimo, et al.
BMC Cardiovascular Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Giuseppe Vergaro, Annamaria Del Franco, Alberto Aimo, et al.
BMC Cardiovascular Disorders (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies
William Suciangto, Haerani Rasyid, A. Vicente, et al.
Nefrología (2024)
Open Access
William Suciangto, Haerani Rasyid, A. Vicente, et al.
Nefrología (2024)
Open Access
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies
William Suciangto, Haerani Rasyid, A. Vicente, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 6, pp. 796-806
Open Access
William Suciangto, Haerani Rasyid, A. Vicente, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 6, pp. 796-806
Open Access
Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients
Ahmed A. Abo Elnaga, Ibrahim Serag, Mohamed A. Alsaied, et al.
International Urology and Nephrology (2024)
Closed Access
Ahmed A. Abo Elnaga, Ibrahim Serag, Mohamed A. Alsaied, et al.
International Urology and Nephrology (2024)
Closed Access
Effectivity and Safety Profile of Tenapanor, a Sodium-Hydrogen Exchanger Isoform 3 Inhibitor, as an Innovative Treatment for Hyperphosphatemia in Chronic Kidney Disease, a Systematic Review of Clinical Studies
William Suciangto, Haerani Rasyid, A. Vicente, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
William Suciangto, Haerani Rasyid, A. Vicente, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Intact fibroblast growth factor 23 tested by a fully automated assay: clinical correlates and prognostic value in chronic systolic heart failure
Giuseppe Vergaro, Annamaria Del Franco, Francesco Gentile, et al.
Research Square (Research Square) (2022)
Open Access
Giuseppe Vergaro, Annamaria Del Franco, Francesco Gentile, et al.
Research Square (Research Square) (2022)
Open Access
Phosphorus metabolism and fibroblast growth factor 23 in chronic kidney disease
Anip Bansal, Michel Chonchol
Elsevier eBooks (2021), pp. 383-396
Closed Access
Anip Bansal, Michel Chonchol
Elsevier eBooks (2021), pp. 383-396
Closed Access
